Vasomune Therapeuticsincis A Private Clinical Stage Biopharmaceutical Company Based In Torontocanadawith An Additional Office In Raleighnorth Carolinafounded In 2014The Company Focuses On Developing Innovative Therapies For Vascular Dysfunction Associated With Various Conditionsincluding Acute Respiratory Distress Syndromeards Sepsisand Stroke The Company S Lead Candidateav 001Is A First In Class Synthetic Peptide That Targets The Tie2 Receptorwhich Is Essential For Vascular Stability And Endothelial Functionav 001 Has Demonstrated Potential In Preclinical Studies By Enhancing Endothelial Cell Survival And Improving Lung Functionit Is Currently In Clinical Development And Has Received Fast Track Designation From The U Sfda For The Prevention Or Treatment Of Moderate To Severe Ards In Hospitalized Patientsvasomune Therapeutics Aims To Address Significant Unmet Medical Needs In The Field Of Vascular Health
No conferences found for this company.
| Company Name | Vasomune Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
